Evaluating Lymph Node T Cell "Clonal Replacement" in a Phase II Trial of Neoadjuvant SBRT plus Cemiplimab versus Chemotherapy plus Cemiplimab in Resectable NSCLC Grant uri icon

Overview

date/time interval

  • March 1, 2025 - February 28, 2026

sponsor award ID

  • MCC CTIF 250906-01

Affiliation